Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
Sponsor
US Department of Veterans Affairs (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT00108290
Collaborator
(none)
1
35
Study Details
Study Description
Brief Summary
In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a combination of chemotherapy and hormone therapy is being given for 6 months followed by surgery to remove the prostate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Chemohormone Therapy Prior to Prostatectomy in High Risk Prostate Cancer
Study Start Date
:
Apr 1, 2004
Study Completion Date
:
Mar 1, 2007
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- High risk prostate cancer without evidence of bone metastasis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VA Maryland Health Care System | Baltimore | Maryland | United States | 21201 |
Sponsors and Collaborators
- US Department of Veterans Affairs
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00108290
Other Study ID Numbers:
- CLIN-003-02F
First Posted:
Apr 15, 2005
Last Update Posted:
Apr 4, 2008
Last Verified:
Apr 1, 2007
Keywords provided by ,
,
Additional relevant MeSH terms: